Atrial Fibrillation and Coronary Artery Disease: Deciding on The Best Antithrombotic Regimen

Jason G. Andrade MD, Marc W. Deyell MD MSc, Laurent Macle MD
DOI: 10.22374/cjgim.v13iSP1.309

ABSTRACT
Atrial fibrillation (AF) is a chronic progressive disease characterized by exacerbations and remissions. Up to 20–30% of patients with AF also have coronary artery disease (CAD). In patients with concomitant AF and CAD, the management of antithrombotic therapy is challenging. Oral anticoagulation (OAC) is indicated for the prevention of AF-related stroke and systemic embolism, whereas antiplatelet therapy is indicated for the prevention of coronary events. Each of these therapeutic avenues offers a relative efficacy benefit (e.g., dual antiplatelet therapy [DAPT] is more effective than OAC alone in reducing cardiovascular death, myocardial infarction, stent thrombosis, and ischemic coronary events in an ACS population), but with a relative compromise (e.g., DAPT is significantly inferior to OAC for the prevention of stroke/systemic embolism in an AF population). The purpose of this review is to explore the current evidence and rationale for antithrombotic treatment strategies in patients with both AF and CAD.
preferred antithrombotic therapeutic regimen for AF patients with ACS or undergoing PCI? (2) Should we use NOACs as part of the dual or triple therapy regimen? (3) What is the preferred P2Y12 inhibitor as part of the combination therapy regimen? (4) What is the optimal duration of triple antithrombotic therapy? (5) What is the optimal antithrombotic therapy for AF patients with stable CAD?

**Question 1 – What Is the Preferred Antithrombotic Therapeutic Regimen for AF Patients With ACS or Undergoing PCI?**

The most complicated scenario for management of AF and CAD is the patient with a strong indication for OAC therapy for stroke prevention (aged ≥ 65 years or CHADS2 score ≥ 1), in whom an acute coronary event has occurred. In this circumstance the patient is at risk for both AF-related stroke/systemic embolism as well as adverse ischemic coronary events (e.g., stent thrombosis and recurrent myocardial infarction). There are three key clinical trials that have been performed in an effort to address the therapeutic dilemma associated with patients requiring oral anticoagulation and dual antiplatelet therapy (Table 1).

The “What Is the Optimal Antiplatelet and Anticoagulation Therapy in Patients With Oral Anticoagulation and Coronary Stenting” (WOEST) study randomized 573 patients with a need for anticoagulation undergoing PCI to dual pathway therapy (OAC and clopidogrel 75mg/day) or to triple antithrombotic therapy (OAC, clopidogrel, and aspirin 80 mg/day).19,20 Treatment was continued for 1 month after BMS placement (35% of patients) and for 1 year after DES placement (65% of patients). The primary outcome of this open-label trial was any

| Table 1. Relative Comparison of the WOEST, PIONEER AF-PCI, RE-DUAL Trials |
|----------------------------------|----------------|-----------------|-----------------|
| **Design**                       | **Woest**      | **Pioneer AF-PCI** | **Re-Dual PCI** |
| Population                       | Multicenter RCT | Multicenter RCT | Multicenter RCT |
| W + A+C                          | 573            | 2124            | 2725            |
| W + C                            | 279            | 697             | 981             |
| W + A+C                          | 697            | 696             | 697             |
| W + A+C                          | 706            | 706             | 763             |
| Follow-up                        | 12 months      | 12 months       | 14 months       |
| Age in years                     | 68.7           | 70.1            | 70.8            |
| Male                             | 74.4%          | 74.4%           | 80.0%           |
| % AF                             | 69%            | 100%            | 100%            |
| Outcomes                         |                |                 |                 |
| • Any Bleeding                   | HR 0.36        | HR 0.59         | HR 0.52**       |
|                                 | 95% CI 0.26–0.50| 95% CI 0.47–0.76| 95% CI 0.42–0.63|
| • Major TMI bleeding             | HR 0.56        | HR 0.66         | HR 0.37*        |
|                                 | 95% CI 0.25–1.27| 95% CI 0.33–1.31| 95% CI 0.20–0.68|
| • MACE                           | HR 0.61        | HR 1.08         | HR 1.13**       |
|                                 | 95% CI 0.38–0.94| 95% CI 0.69–1.68| 95% CI 0.90–1.43|

W = warfarin; A = ASA 81 mg daily; C = clopidogrel 75 mg daily; R15 = rivaroxaban 15 mg daily; R2.5 = rivaroxaban 2.5 mg bid; D110 = dabigatran 110 mg bid; D150 = dabigatran 150 mg bid.

**ISTH and clinically relevant non-major bleeding.
1WOEST = death, myocardial infarction, stroke, target vessel revascularization, stent thrombosis.
2PIONEER AF-PCI = cardiovascular death, myocardial infarction, stroke.
3RE-DUAL PCI = Death, revascularization, myocardial infarction, stroke, systemic thromboembolism.
bleeding event within 1 year of follow-up (e.g., TIMI major plus minor). Dual pathway therapy was associated with a significant reduction in overall bleeding complications (19.4% with DT vs. 44.4% with TT), without significant differences in major bleeds (3.2% vs. 5.6%). Though not powered to detect differences in major thrombotic outcomes, the combined endpoint of major adverse cardiac and cerebrovascular events (MACCE – death, myocardial infarction, stroke, target vessel revascularization, stent thrombosis) was significantly reduced with dual pathway therapy (11.1% vs. 17.6) as was all-cause mortality (2.5% vs. 6.4%; P = 0.027).

The “Prevention of bleeding in patients with AF undergoing PCI” (PIONEER AF-PCI) study randomized 2,124 patients with non-valvular AF undergoing PCI for ACS (51%) or for stable CAD to receive, in a 1:1:1 ratio: (1) P2Y12 inhibitor (94% clopidogrel) plus rivaroxaban 15 mg daily (dual pathway) for 12 months (709 patients), (2) DAPT plus rivaroxaban 2.5 mg twice daily (reduced dose triple antithrombotic therapy) for 1, 6 or 12 months (709 patients), or (3) traditional triple antithrombotic therapy with warfarin (target INR 2-3) plus DAPT for 1, 6, or 12 months (706 patients). The primary safety endpoint, consisting of clinically significant bleeding (e.g., TIMI major plus minor), was lower in the dual pathway and reduced dose triple antithrombotic therapy groups when compared to the group receiving traditional triple antithrombotic therapy with warfarin (16.8% in patients treated with dual pathway therapy, 18% in patients treated with reduced dose triple antithrombotic therapy, and 26.7% in patients treated with traditional triple antithrombotic therapy). Similar to WOEST there was a non-significant reduction in major bleeding dual pathway and reduced dose triple antithrombotic therapy groups when compared to the group receiving traditional triple antithrombotic therapy with warfarin.

The “Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation” (RE-DUAL PCI) trial randomized 2,725 patients with non-valvular AF undergoing PCI for ACS (51%) or stable CAD to receive: (1) dual pathway therapy with dabigatran 110mg bid plus P2Y12 inhibitor (D110 - 981 patients), (2) dual pathway therapy with dabigatran 150mg bid plus P2Y12 inhibitor (D150 - 763 patients), or (3) traditional triple antithrombotic therapy with warfarin (target INR 2.3) plus a P2Y12 inhibitor (clopidogrel or ticagrelor) plus ASA (981 patients). In the triple antithrombotic therapy group aspirin was discontinued after 1 month (in patients with BMS) or after 3 months (in patients with DES), however the P2Y12 inhibitor was continued for 12-months post-PCI. The primary outcome was ISTH major or clinically relevant non-major bleeding, which was significantly reduced in both dual pathway therapy groups when compared to triple antithrombotic therapy (11.5% absolute reduction with D110 and 5.5% absolute reduction with D150). In secondary efficacy analyses both dual pathway therapy groups significant reduced ISTH major bleeding (4.2% absolute reduction with D110 and 2.8% absolute reduction with D150), and TIMI major bleeding (2.4% absolute reduction with D110 and 1.8% absolute reduction with D150). While the study was underpowered to detect differences in thromboembolic events, the rates of death, myocardial infarction, stroke, or stent thrombosis were similar across the three groups, the use of dual pathway therapy was non-inferior for the composite efficacy endpoint (thromboembolic events).

There are several notable limitations to the above trials. Firstly, a large proportion of patients were undergoing elective PCI (72% in WOEST, 48% in PIONEER AF-PCI, and 44% in RE-DUAL), meaning the rate relative risk of coronary outcomes may be underestimated. Second, measures to decrease bleeding risk were underutilized, suggesting that the observed bleeding rate may be higher than contemporary practice. Third, it is unknown whether the results of PIONEER AF-PCI and RE-DUAL PCI would have been similar had the dual pathway therapy groups utilized a VKA, or if the triple therapy group utilized a standard-dose NOAC.

While each of the trials were individually underpowered to detect meaningful differences in the incidence of ischemic events a limited meta-analysis of these randomized trials demonstrated that the use of dual pathway therapy was associated with a significant reduction in major bleeding events (2.22% vs. 3.78%; OR 0.58, 95%CI 0.39-0.86), without an excess in the occurrence of MI (3.58% vs. 3.21%; OR 0.96), stent thrombosis (1.02% vs. 0.77%; OR 0.95), or stroke (1.35% vs. 1.43%).

However, the meta-analysis focused only on the comparison between dual pathway therapy and triple antithrombotic therapy. We have performed a larger network meta-analysis of 114,887 ACS patients in 10 randomized and 38 non-randomized studies to examine the relative risks/benefits of DAPT vs. dual pathway therapy versus triple antithrombotic therapy. In comparison to DAPT both dual pathway therapy and triple antithrombotic therapy were associated with a significantly higher incidence of major bleeding and with a significant reduction in stroke, but no significant effect on myocardial infarction or all-cause mortality (Figure 1). Compared to dual pathway therapy, triple antithrombotic therapy demonstrated significantly more major bleeding (OR 1.54; 95%CI 1.18-2.00), a trend towards less myocardial infarction (OR 0.82; 95%CI 0.66-1.03) and stent thrombosis (OR 0.66; 95%CI 0.42-1.03), with no differential effect on stroke or all-cause mortality.
Question 2 – Should We Use NOACs As Part of the Dual or Triple Therapy Regimen?
It has been postulated that the use of NOACs may be beneficial given the increased risk of fatal and nonfatal bleeding events (including intracranial hemorrhage) observed with dual pathway or triple antithrombotic therapy. Collectively the phase 3 clinical trials studies comparing NOAC therapy to warfarin demonstrated a non-significant 14% reduction in major bleeding with NOAC therapy when compared to warfarin (95%CI 0.73-1.00). The majority of this benefit was achieved through a significant reduction in hemorrhagic stroke, and subdural, epidural, and subarachnoid bleeding (RR 0.48; 95%CI 0.39-0.59), which was counterbalanced by an increase in gastrointestinal bleeding (RR 1.25; 95%CI 1.01–1.55).

For the subset of subjects (24–38%; total 21,722 patients) who received combination OAC and antiplatelet therapy the use of a standard-dose NOAC was not associated with any significant difference in outcomes, however non-significant trends were observed in terms of reduction in major bleeding (OR 0.94; 95%CI 0.80-1.10), all-cause mortality (OR 0.91; 95%CI 0.79-1.04), and stroke (OR 0.89; 95%CI 0.62-1.30); with a non-significant increase in the rates of myocardial infarction with NOAC therapy (OR 1.24; 95%CI 0.98-1.57) when compared to warfarin.

Question 3 – What Is the Preferred P2Y12 Inhibitor As Part of the Combination Therapy Regimen?
In patients without a need for OAC, the antiplatelet guidelines recommend the use of prasugrel or ticagrelor in preference to clopidogrel for the management of non-ST-segment elevation ACS and ST-elevation myocardial infarction. This is because of their greater efficacy at reducing recurrent MI (11% reduction with prasugrel; 15% reduction with ticagrelor), and stent thrombosis (52% reduction with prasugrel; 26% reduction for ticagrelor). However, these agents are not recommended as a part of a combination therapy owing to their greater propensity of bleeding. As such, clopidogrel is the preferred P2Y12 inhibitor when used in combination therapies with an OAC.

Questions 4 – What Is the Optimal Duration of Triple Antithrombotic Therapy?
The benefit of triple antithrombotic therapy in reducing ischemic outcomes is established in selected subgroups (i.e., those undergoing high-risk PCI), however this benefit must be balanced against the increased bleeding risk with this therapeutic regimen (Figure 2).

The “Intracoronary Stenting and Antithrombotic Regimen-Testing of a 6-Week Versus a 6-Month Clopidogrel Treatment Regimen in Patients with Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-Eluting Stenting” (ISAR-TRIPLE) study randomized patients receiving OAC to 6 weeks or 6 months of triple antithrombotic therapy (307 patients in each group). All patients underwent PCI (33.2% with ACS). The primary composite endpoint included death, MI, stent thrombosis, stroke, or TIMI major bleeding. Although underpowered, there was no difference in composite outcome (cardiac death, MI, stent thrombosis, or ischemic stroke - 4.0% vs. 4.3%; HR 0.93, 95%CI 0.43-2.05), TIMI major bleeding...
(5.3% vs. 4.0%; HR 1.35, 95%CI 0.64-2.84), or death (4.0% vs. 5.2%; HR 0.75, 95% CI 0.35-1.59). A post-hoc landmark analysis from 6 weeks to 9 months (i.e. excluding the period where both groups were on TT) demonstrated a significant reduction in any bleeding in the 6 weeks group (20.5% vs. 27.9%; HR 0.68, 95%CI 0.47-0.98). In addition, the ischemic outcomes did not differ between the 51% of patients in PIONEER AF-PCI used TT durations shorter than 12 months, compared to those who were on TT for a year. On balance, these findings suggest shortening the triple antithrombotic therapy course to ≤ 6 months, and thereafter continuing with OAC and clopidogrel, is reasonable in patients at elevated bleeding risk.

**Question 5 – What Is the Optimal Antithrombotic Therapy for AF Patients With Stable CAD?**

For patients with both AF and CAD the question that dominates is whether OAC therapy alone is an adequate substitute for ASA, or whether ASA should be added to OAC therapy on the rationale that the anticoagulant effect of a VKA combined with the antiplatelet effect of ASA may enhance antithrombotic efficacy. Historically several studies have evaluated this question. These studies randomized post myocardial infarction patients to ASA alone vs. combined warfarin and aspirin therapy, or ASA alone versus warfarin alone versus combined warfarin and aspirin therapy. Collectively these studies demonstrated that combination therapy was associated with a reduction in the combined endpoint of death/non-fatal MI/non-fatal stroke (OR 0.73; 95%CI 0.63-0.84) with a reduction in the rate of myocardial infarction (OR 0.70; 95%CI 0.52-0.95) and stroke (RR 0.43; 95%CI 0.27-0.70), but an increase in the risk of bleeding (OR 2.32; 95%CI 1.63-3.29), when compared to ASA monotherapy. Interestingly, OAC monotherapy was associated with similar rates of death, MI, and stroke (e.g. 16.7% in warfarin group vs. 15.0% in Warfarin plus ASA group; P = 0.18) but lower rates of bleeding compared to combined OAC and aspirin therapy (e.g., overall bleeding 2.82% vs. 3.27%).

When these studies are put together in a network meta-analysis (132,657 CAD patients in 13 randomized and 7 non-randomized studies) OAC monotherapy was associated with significantly less major bleeding (OR 0.76; 95%CI 0.63-0.90), and a lower all-cause mortality (OR 0.82; 95%CI 0.72-0.94), with a trend towards reduced MI (OR 0.84; 95%CI 0.70-1.00) vs. combination therapy. Therefore, for patients at risk of AF-associated stroke/systemic embolism the cumulative evidence base supports the use of OAC alone as it provides protection against both stroke and coronary events. The addition of antiplatelet therapy to OAC confers an increased risk of adverse bleeding outcomes while providing only limited benefit on coronary outcomes.

**Summary**

General recommendations for antithrombotic therapy include the following (see Figure 1):

1. For patients at low risk of AF-associated stroke (age < 65 years and CHADS2 Score = 0) OAC therapy of the coronary generally not recommended. The disease should follow the recommendations found in the 2018 CCS/CAIC Focused Update of the Guidelines for the Use of Antiplatelet Therapy.
2. For patients at high risk of AF-associated stroke (age ≥ 65 years or CHADS2 Score ≥ 1) and stable CAD we recommend OAC alone.
3. For patients at high risk of AF-associated stroke (age ≥ 65 years or CHADS2 Score ≥ 1) undergoing elective or low-risk PCI, OAC combined with clopidogrel (dual therapy) for one year should be employed.

4. For patients at high risk of AF-associated stroke (age ≥ 65 years or CHADS2 Score ≥ 1) undergoing high-risk PCI, OAC combined with ASA and clopidogrel (triple therapy) should be employed for up to 6 months post PCI, followed by dual therapy with OAC plus clopidogrel until one-year post PCI.

5. When OAC is used a NOAC is preferred.

6. Clopidogrel is the preferred antiplatelet agent in dual pathway or triple therapy.

**Conclusion**

The management of patients with concomitant AF and CAD is challenging and requires a comprehensive assessment of the competing risks of the therapeutic options. For most patients OAC alone can be used for stable CAD, with triple therapy used for a short period (<6 months) after ACS or high-risk PCI, followed by dual therapy until 12 months post event.

**References**


